OBJECTIVE: To investigate the effects of cinnamaldehyde (CA), an active and major compound in cinnamon, on glucose metabolism and insulin resistance in C57BLKS/J db/db mice. METHODS: Sixteen male C57BLKS db/db mice were randomly divided into control and CA treatment groups. CA was given (20 mg x kg(-1) x day(-1), p. o.) for 4 weeks. Pure water was given to control and db/+ mice. Subsequently, the levels of fasting blood glucose (FBG), fasting serum insulin, triglyeride, cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and free fatty acids (FFA), as well as the mRNA content of adiponectin and tumor necrosis factor (TNF)-alpha in adipose tissue, glucose transporter type 4 (GLUT-4) in skeletal muscle, and protein expressions of Akt, phospho-Akt (Thr308), AMPKalpha, phospho-AMPKalpha (Thr172) in skeletal muscle were measured. RESULTS: 1) CA decreased serum levels of FBG and insulin as well as body weight in db/db mice; 2) CA increased serum HDL-C levels; 3) CA significantly decreased the mRNA expression of TNF-alpha in adipose tissue and upregulated mRNA expression of GLUT-4 in skeletal muscle; 4) protein expression of p-Akt was increased in CA-treated mice, but Akt, AMPKalpha and p-AMPKalpha showed no change. CONCLUSION: CA has antihyperglycemic and antihyperlipidemic actions in db/db mice and could be useful in the treatment of type-2 diabetes.
OBJECTIVE: To investigate the effects of cinnamaldehyde (CA), an active and major compound in cinnamon, on glucose metabolism and insulin resistance in C57BLKS/J db/db mice. METHODS: Sixteen male C57BLKS db/db mice were randomly divided into control and CA treatment groups. CA was given (20 mg x kg(-1) x day(-1), p. o.) for 4 weeks. Pure water was given to control and db/+ mice. Subsequently, the levels of fasting blood glucose (FBG), fasting serum insulin, triglyeride, cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and free fatty acids (FFA), as well as the mRNA content of adiponectin and tumor necrosis factor (TNF)-alpha in adipose tissue, glucose transporter type 4 (GLUT-4) in skeletal muscle, and protein expressions of Akt, phospho-Akt (Thr308), AMPKalpha, phospho-AMPKalpha (Thr172) in skeletal muscle were measured. RESULTS: 1) CA decreased serum levels of FBG and insulin as well as body weight in db/db mice; 2) CA increased serum HDL-C levels; 3) CA significantly decreased the mRNA expression of TNF-alpha in adipose tissue and upregulated mRNA expression of GLUT-4 in skeletal muscle; 4) protein expression of p-Akt was increased in CA-treated mice, but Akt, AMPKalpha and p-AMPKalpha showed no change. CONCLUSION: CA has antihyperglycemic and antihyperlipidemic actions in db/db mice and could be useful in the treatment of type-2 diabetes.
Authors: Omnia A A Nour; George S G Shehatou; Mona Abdel Rahim; Mohammed S El-Awady; Ghada M Suddek Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-07-30 Impact factor: 3.000
Authors: Michael Buenor Adinortey; Rosemary Agbeko; Daniel Boison; William Ekloh; Lydia Enyonam Kuatsienu; Emmanuel Ekow Biney; Obed O Affum; Jeffery Kwarteng; Alexander Kwadwo Nyarko Journal: Evid Based Complement Alternat Med Date: 2019-04-18 Impact factor: 2.629
Authors: Cicero L T Chang; Yenshou Lin; Arlene P Bartolome; Yi-Ching Chen; Shao-Chih Chiu; Wen-Chin Yang Journal: Evid Based Complement Alternat Med Date: 2013-04-04 Impact factor: 2.629